Gilead Sciences, Inc. (GIS.DE)

61,52 +0,44 (+0,72%) In data: 02:57PM CEST. Mercato aperto.

Gilead Sciences, Inc.

333 Lakeside Drive
Foster City, CA 94404
United States
650 574 3000
https://www.gilead.com

Settore/i: Healthcare
Settore: Drug Manufacturers - General
Impiegati a tempo pieno: 18.000

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Daniel P. O'Day	Chairman & CEO	6,56M	N/D	1964
Mr. Andrew D. Dickinson	Chief Financial Officer	2,5M	N/D	1970
Ms. Deborah H. Telman	Executive VP of Corporate Affairs, General Counsel & Corporate Secretary	2,4M	N/D	1965
Ms. Johanna Mercier	Chief Commercial Officer	2,9M	N/D	1970
Dr. Merdad V. Parsey M.D., Ph.D.	Chief Medical Officer	2,62M	N/D	1964
Ms. Sandra Patterson	Senior VP, Corporate Controller & Principal Accounting Officer	N/D	N/D	1967
Ms. Jacquie Ross C.F.A.	Vice President of Investor Relations	N/D	N/D	N/D
Ms. Jyoti K. Mehra	Executive Vice President of Human Resources	N/D	N/D	1976
Dr. Linda Slanec Higgins Ph.D.	Senior Vice President of Research, Innovation & Portfolio	N/D	N/D	1962
Dr. Rudolf Ertl	Senior Vice President of Commercial Operations of Australia, Canada, Europe	N/D	N/D	1946

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Governance aziendale

L'ISS Governance QualityScore di Gilead Sciences, Inc. al 29 aprile 2024 è 1. I criteri di valutazione fondamentali sono revisione: 3; Consiglio di Amministrazione: 4; diritti degli azionisti: 1; retribuzione: 3.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.